...
首页> 外文期刊>Frontiers in Medicine >Lung Ultrasound in the Diagnosis of COVID-19 Pneumonia: Not Always and Not Only What Is COVID-19 “Glitters”
【24h】

Lung Ultrasound in the Diagnosis of COVID-19 Pneumonia: Not Always and Not Only What Is COVID-19 “Glitters”

机译:肺超声在Covid-19肺炎的诊断中:并不总是不仅是什么,不仅是什么是Covid-19“闪闪发光”

获取原文

摘要

Background: In the current coronavirus disease-2019 (COVID-19) pandemic, lung ultrasound (LUS) has been extensively employed to evaluate lung involvement and proposed as a useful screening tool for early diagnosis in the emergency department (ED), prehospitalization triage, and treatment monitoring of COVID-19 pneumonia. However, the actual effectiveness of LUS in characterizing lung involvement in COVID-19 is still unclear. Our aim was to evaluate LUS diagnostic performance in assessing or ruling out COVID-19 pneumonia when compared with chest CT (gold standard) in a population of SARS-CoV-2-infected patients. Methods: A total of 260 consecutive RT-PCR confirmed SARS-CoV-2-infected patients were included in the study. All the patients underwent both chest CT scan and concurrent LUS at admission, within the first 6–12 h of hospital stay. Results: Chest CT scan was considered positive when showing a “typical” or “indeterminate” pattern for COVID-19, according to the RSNA classification system. Disease prevalence for COVID-19 pneumonia was 90.77%. LUS demonstrated a sensitivity of 56.78% in detecting lung alteration. The concordance rate for the assessment of abnormalities by both methods increased in the case of peripheral distribution and middle-lower lung location of lesions and in cases of more severe lung involvement. A total of nine patients had a “false-positive” LUS examination. Alternative diagnosis included chronic heart disease (six cases), bronchiectasis (two cases), and subpleural emphysema (one case). LUS specificity was 62.50%. Collateral findings indicative of overlapping conditions at chest CT were recorded also in patients with COVID-19 pneumonia and appeared distributed with increasing frequency passing from the group with mild disease (17 cases) to that with severe disease (40 cases). Conclusions: LUS does not seem to be an adequate tool for screening purposes in the ED, due to the risk of missing some lesions and/or to underestimate the actual extent of the disease. Furthermore, the not specificity of LUS implies the possibility to erroneously classify pre-existing or overlapping conditions as COVID-19 pneumonia. It seems more safe to integrate a positive LUS examination with clinical, epidemiological, laboratory, and radiologic findings to suggest a “virosis.” Viral testing confirmation is always required.
机译:背景:在目前的冠状病毒病 - 2019年(Covid-19)大流行,肺超声(LUS)已被广泛用于评估肺部受累,并提出作为急诊部(ED),急诊期的早期诊断的有用筛选工具,和Covid-19肺炎的治疗监测。然而,LUS在Covid-19中表征肺部参与的实际有效性仍然不清楚。我们的目标是评估评估或排除Covid-19肺炎的诊断性能,与SARS-COV-2感染患者患者的胸部CT(金标准)相比。方法:总共260例连续RT-PCR证实SARS-COV-2感染患者均包括在研究中。所有患者均在入院的前6-12小时内接受胸部CT扫描和同时延迟。结果:根据RSNA分类系统显示Covid-19的“典型”或“不确定”模式,胸部CT扫描被认为是正的。 Covid-19肺炎的疾病患病率为90.77%。 LUS在检测肺部改变时表现出56.78%的敏感性。两种方法评估异常评估的一致性率在病变的外周分布和中下肺部位置以及更严重的肺部受累情况的情况下增加。共有九个患者有一个“假阳性”LUS检查。替代诊断包括慢性心脏病(6例),支气管扩张(两种情况)和副肺气肿(一个案例)。 LUS特异性为62.50%。患有Covid-19肺炎的患者还记录了表明胸部CT的重叠条件的附带结果,并随着从患有轻度疾病(17例)的频率增加,患有严重疾病(40例)的频率增加。结论:由于缺少一些病变和/或低估了疾病的实际程度,因此LUS似乎并不是一种用于筛选ED中的目的的适当工具。此外,LU的不特异性意味着可能错误地将预先存在或重叠条件作为Covid-19肺炎分类。综合患有临床,流行病学,实验室和放射学发现,似乎更安全地融为一体,以表明“病毒病”。始终需要病毒检测确认。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号